BRPI1015921A2 - agonistas de gpr119 - Google Patents

agonistas de gpr119

Info

Publication number
BRPI1015921A2
BRPI1015921A2 BRPI1015921A BRPI1015921A BRPI1015921A2 BR PI1015921 A2 BRPI1015921 A2 BR PI1015921A2 BR PI1015921 A BRPI1015921 A BR PI1015921A BR PI1015921 A BRPI1015921 A BR PI1015921A BR PI1015921 A2 BRPI1015921 A2 BR PI1015921A2
Authority
BR
Brazil
Prior art keywords
gpr119 agonists
gpr119
agonists
Prior art date
Application number
BRPI1015921A
Other languages
English (en)
Portuguese (pt)
Inventor
Ana Belen Bueno Melendo
Bin Liu
David Gene Barrett
Jeffry Bernard Franciskovich
Kumiko Takeuchi
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43449712&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI1015921(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BRPI1015921A2 publication Critical patent/BRPI1015921A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
BRPI1015921A 2009-07-15 2010-07-12 agonistas de gpr119 BRPI1015921A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09382114 2009-07-15
US24544509P 2009-09-24 2009-09-24
PCT/US2010/041645 WO2011008663A1 (en) 2009-07-15 2010-07-12 Gpr119 agonists

Publications (1)

Publication Number Publication Date
BRPI1015921A2 true BRPI1015921A2 (pt) 2016-04-26

Family

ID=43449712

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1015921A BRPI1015921A2 (pt) 2009-07-15 2010-07-12 agonistas de gpr119

Country Status (24)

Country Link
US (1) US8207344B2 (enExample)
EP (1) EP2454251A1 (enExample)
JP (1) JP5715127B2 (enExample)
KR (1) KR101365854B1 (enExample)
CN (1) CN102471313B (enExample)
AR (1) AR077638A1 (enExample)
AU (1) AU2010273642B2 (enExample)
BR (1) BRPI1015921A2 (enExample)
CA (1) CA2764906C (enExample)
CO (1) CO6480977A2 (enExample)
CR (1) CR20120012A (enExample)
DO (1) DOP2012000006A (enExample)
EA (1) EA020540B1 (enExample)
EC (1) ECSP12011606A (enExample)
IL (1) IL216776A0 (enExample)
MA (1) MA33428B1 (enExample)
MX (1) MX2012000704A (enExample)
NZ (1) NZ597125A (enExample)
PE (1) PE20121045A1 (enExample)
SG (1) SG177646A1 (enExample)
TN (1) TN2012000002A1 (enExample)
TW (1) TWI429634B (enExample)
WO (1) WO2011008663A1 (enExample)
ZA (1) ZA201200227B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS20050532A (sr) 2003-01-14 2007-12-31 Arena Pharmaceuticals Inc., Derivati 1,2,3-trisupstituisanog arila i heteroarila kao modulatori metabolizma za profilaksu i tretman poremećaja povezanih sa njim, kao što su dijebetes i hiperglikemija
EP2146210A1 (en) 2008-04-07 2010-01-20 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY
JP2013522279A (ja) 2010-03-18 2013-06-13 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糖尿病及び関連状態の治療で用いるgpr119作動薬とddp−iv阻害薬リナグリプチンの組合せ
CN103221410B (zh) 2010-09-22 2017-09-15 艾尼纳制药公司 Gpr119受体调节剂和对与其相关的障碍的治疗
US20140018371A1 (en) * 2011-04-01 2014-01-16 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
US8957062B2 (en) 2011-04-08 2015-02-17 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment
WO2012170702A1 (en) * 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
KR101913619B1 (ko) 2011-06-09 2018-12-28 리젠 파마슈티컬스 소시에떼 아노님 Gpr-119의 조절제로서의 신규한 화합물
EP2720544B1 (en) 2011-06-16 2016-12-21 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds, compositions containing such compounds, and methods of treatment
WO2013048916A1 (en) * 2011-09-30 2013-04-04 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment
EP2771000B1 (en) 2011-10-24 2016-05-04 Merck Sharp & Dohme Corp. Substituted piperidinyl compounds useful as gpr119 agonists
WO2013062835A1 (en) * 2011-10-24 2013-05-02 Merck Sharp & Dohme Corp. Substituted piperidinyl compounds useful as gpr119 agonists
CA2855009C (en) 2011-11-15 2019-07-09 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds useful as gpr119 agonists
WO2013187646A1 (en) * 2012-06-12 2013-12-19 Chong Kun Dang Pharmaceutical Corp. Piperidine derivatives for gpr119 agonist
AU2013290100A1 (en) 2012-07-11 2015-01-29 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
WO2014052619A1 (en) * 2012-09-27 2014-04-03 Irm Llc Piperidine derivatives and compositions as modulators of gpr119 activity
HUE045926T2 (hu) 2013-11-26 2020-01-28 Chong Kun Dang Pharmaceutical Corp Amid-származékok GPR119 agonistákhoz
KR101651505B1 (ko) * 2014-05-02 2016-08-29 현대약품 주식회사 싸이클로 헥센 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 대사성 질환의 예방 또는 치료용 약학적 조성물
CA3002540C (en) 2015-01-06 2023-11-07 Arena Pharmaceuticals, Inc. Use of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid for treating conditions related to the s1p1 receptor
JP6838744B2 (ja) 2015-06-22 2021-03-03 アリーナ ファーマシューティカルズ, インコーポレイテッド S1P1レセプター関連障害における使用のための(R)−2−(7−(4−シクロペンチル−3−(トリフルオロメチル)ベンジルオキシ)−1,2,3,4−テトラヒドロシクロペンタ[b]インドール−3−イル)酢酸(化合物1)の結晶性L−アルギニン塩
CN110520124A (zh) 2017-02-16 2019-11-29 艾尼纳制药公司 用于治疗原发性胆汁性胆管炎的化合物和方法
JP7397011B2 (ja) 2018-06-06 2023-12-12 アリーナ ファーマシューティカルズ, インコーポレイテッド S1p1受容体に関連する状態を治療する方法
MX2022010548A (es) 2020-02-28 2022-09-23 Kallyope Inc Agonistas de gpr40.
MX2022014505A (es) 2020-05-19 2022-12-13 Kallyope Inc Activadores de la ampk.
CA3183575A1 (en) 2020-06-26 2021-12-30 Iyassu Sebhat Ampk activators

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS20050532A (sr) * 2003-01-14 2007-12-31 Arena Pharmaceuticals Inc., Derivati 1,2,3-trisupstituisanog arila i heteroarila kao modulatori metabolizma za profilaksu i tretman poremećaja povezanih sa njim, kao što su dijebetes i hiperglikemija
EP2059517A1 (en) * 2006-08-30 2009-05-20 Biovitrum AB (publ) Pyrimidine compounds for treating gpr119 related disorders
US7638541B2 (en) * 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
ES2499018T3 (es) * 2007-09-20 2014-09-26 Irm Llc Compuestos y composiciones como moduladores de la actividad de GPR119

Also Published As

Publication number Publication date
TWI429634B (zh) 2014-03-11
WO2011008663A1 (en) 2011-01-20
MA33428B1 (fr) 2012-07-03
TW201114757A (en) 2011-05-01
NZ597125A (en) 2013-08-30
JP5715127B2 (ja) 2015-05-07
KR20120024964A (ko) 2012-03-14
CN102471313A (zh) 2012-05-23
KR101365854B1 (ko) 2014-02-21
AU2010273642A1 (en) 2012-01-19
CA2764906A1 (en) 2011-01-20
PE20121045A1 (es) 2012-08-09
ECSP12011606A (es) 2012-02-29
AR077638A1 (es) 2011-09-14
DOP2012000006A (es) 2012-01-31
EA201270169A1 (ru) 2012-06-29
TN2012000002A1 (en) 2013-09-19
US8207344B2 (en) 2012-06-26
SG177646A1 (en) 2012-02-28
CO6480977A2 (es) 2012-07-16
CN102471313B (zh) 2014-06-04
ZA201200227B (en) 2013-06-26
MX2012000704A (es) 2012-03-07
CA2764906C (en) 2014-06-10
IL216776A0 (en) 2012-03-01
EA020540B1 (ru) 2014-11-28
EP2454251A1 (en) 2012-05-23
JP2012533546A (ja) 2012-12-27
US20110015199A1 (en) 2011-01-20
AU2010273642B2 (en) 2014-03-13
CR20120012A (es) 2012-03-28

Similar Documents

Publication Publication Date Title
FIC20250029I1 (fi) neratinibi
FIC20230025I1 (fi) neratinibi
ZA201200227B (en) Gpr119 agonists
DK2506745T3 (da) Patron-ekstraktionsindretning
BR112012004536A2 (pt) dispositivo
BRPI1008774A2 (pt) espiroamida substituída
UA19989S (uk) Пристрій гіпертермомасажний
EP2474540A4 (en) GPR119 AGONIST
DK2511282T3 (da) Uracylspirooxetannukleosider
BR112012010974A2 (pt) dispositivo
BRPI1008827A2 (pt) deisobutenizador
BRPI0807911A2 (pt) Agonistas de alfa2c adrenorreceptor
BRPI1014968A2 (pt) subalargador
BRPI1008070A2 (pt) tricianoboratos
BR112012004964A2 (pt) girocóptero
DK2493768T3 (da) Etiketfjernelses-indretning
BR112012002883A2 (pt) dispositivo
EP2479211A4 (en) FLUOR RUBBER COMPOSITION
FR2947857B1 (fr) Agencement de deshuileur
EP2509287A4 (en) SLIDING AND TILTING MECHANISM
BR112012002824A2 (pt) agonistas de receptor de esfingosina-1-fosfato
BRPI0917563A2 (pt) porta-objeto
BRPI1010159A2 (pt) bistuti
ITPD20090053U1 (it) Paradordi per banchine
BR112012007885A2 (pt) dispositivo de retensão

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]